Use of fulvestrant in the treatment of resistant breast cancer
OwnerBeat Thurlimanninventor
Life of this patent
Estimating the term…
Abstract
The invention relates to the use of fulvestrant in the treatment of breast cancer in patients who have previously been treated with an Selective Estrogen Receptor Modulator (SERM) and an aromatase inhibitor.
Claims10
A method for the treatment of breast cancer in a patient previously treated with an aromatase inhibitor and to have failed with such previous treatment by the administration of a therapeutically effective amount of fulvestrant.
A method for the treatment of breast cancer in a patient previously treated with an aromatase inhibitor and a SERM and to have failed with such previous treatment by the administration of a therapeutically effective amount of fulvestrant.
A method as claimed in any claim from 1 to 3 wherein the aromatase inhibitor is anastrazole.
A method as claimed in any method from 2 to 4 wherein the SERM is tamoxifen.
Use of fulvestrant in the preparation of a medicament for the treatment of a patient with breast cancer who previously has been treated with an aromatase inhibitor and has failed with such previous treatment.
Use of fulvestrant in the preparation of a medicament for the treatment of a patient with breast cancer who previously has been treated with an aromatase inhibitor and a SERM, and has failed with such previous treatment.
A use as claimed in any claim from 6 to 8 wherein the aromatase inhibitor is anastrazole.
A use as claimed in any claim from 7 to 9 wherein the SERM is tamoxifen.
Dependencies are inferred from the claim text.